Best Genomics Companies in Ohio, United States
The 33 best Genomics companies in Ohio, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Forge Biologics.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Ohio
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Forge Biologics Developer of gene therapeutic solutions for treating multiple diseases | $330M | 49 mo ago | Acquired | 118 | Jaysson Eicholtz Co-Founder | WordPress Block EditorWordPressApple iCloud Mail+25 | 27 patents Improving viral vector manufacturing for gene therapy: safer AAV production and adenoviral helpers | — |
| 2 | Juventas Therapeutics Developer of non-viral gene therapies to treat cardiovascular diseases that target natural repair pathways | $107M | 60 mo ago | Deadpooled | 1 | — | — | — | — |
| 3 | Cleveland Diagnostics Developer of diagnostics technology to detect cancer in early stage 53Funding top 21%Moat top 31%Growth top 35%Tech top 39% All 8 signals ▾Fundingtop 21% Moattop 31% Growthtop 35% Techtop 39% Talentbottom 49% Globalbottom 37% Marketbottom 36% Newsbottom 22% Funding: Raised $96.8M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 53/100 | $97M | 12 mo ago | Series E | 40 | Arnon Chait President And Ceo | Squarespace CommerceSquarespaceSentry+25 | — | — |
| 4 | Assurex Health Personalized neuropsychiatric medicine | $84M | 130 mo ago | Acquired | 390 | — | — | — | — |
| 5 | ParaGen Technologies Developer of tissue engineering technologies | $12M | 59 mo ago | Series A | 16 | Flavio Lobato Co-Founder | — | — | — |
| 6 | Diagnostic Hybrids Developer of molecular diagnostics kits for infectious diseases | $10M | 266 mo ago | Acquired | 1,103 | — | — | 74 patents Chimeric receptor and fluorescence assays for rapid autoimmune and viral diagnostics | — |
| 7 | GLC Biotechnology Developer of DNA test for early detection of colon cancer | $10M | 37 mo ago | Funding Raised | — | Baochuan CEO | — | — | — |
| 8 | Ischemia Care Provider of molecular diagnostic solutions to stroke | $6M | 90 mo ago | Series A | 6 | — | — | — | — |
| 9 | Myonexus Therapeutics Genetic medicine company engineering solutions for rare diseases | $2M | 106 mo ago | Acquired | 4 | Michael Triplett Co-Founder & CEO | — | — | — |
| 10 | Scientific Data Analysis Platform Provider of data and sequence analysis platform for healthcare researchers | $2M | 21 mo ago | Funding Raised | — | Andrey Kartashov Co-Founder | — | — | — |
| 11 | Nano Detection Technology Chips for rapid detection of multiple biomarkers | $2M | 183 mo ago | Series A | 5 | Douglas Harris CEO | — | — | — |
| 12 | Cell X Technologies Developer of regenerative medicine to measure and manage human cell sources | $1M | 85 mo ago | Funding Raised | 9 | George Muschler Founder & CSO | WordPressMySQLPHP+21 | 70 patents Patents concentrated in health & consumer products | — |
| 13 | GenomeNext Genomic analysis platform for next gen sequencing | $1M | 116 mo ago | Deadpooled | 5 | — | — | — | — |
| 14 | AnalizaDx Provider of protein-based diagnostics for cancer | $300K | 240 mo ago | Seed | — | Arnon Chait Co-Founder | — | — | — |
| 15 | Milo Biotechnology Developer of gene therapies for the treatment of muscular dystrophy | $250K | 119 mo ago | Seed | — | Al Hawkins CEO and Founder | — | — | — |
Top 12 Genomics companies in Ohio
#1
Series E · Cleveland, Ohio · founded 2013 · 40 employees$96.8Mraised▾
ClevelandDx has developed diagnostics technology to detect cancer in early-stage. The company uses specific biomarkers to distinguish the non-cancerous and cancerous conditions. The expression of these biomarkers is based on a proprietary technology that separates protein isoforms, based on structure.
- Oct 2025Series E$14.4M
- Jan 2024Series E$75M
- Feb 2021Series D$19.4M
- Nov 2016Conventional Debt—
#2
Funding Raised · Cincinnati, Ohio · founded 2015$2.3Mraised▾
Provider of data and sequence analysis platform for healthcare researchers. The company has developed a next-generation data analysis platform that assists researchers and scientists to analyze genomic sequences and more. The platform provides tools for comparative analysis of data, workflow management, and automated prototyping.
- Jan 2025Grant (prize money)$306.5K
- Sep 2020Grant (prize money)$2M
#3
Acquired · Columbus, Ohio · founded 2020 · 118 employees$330Mraised▾
Developer of gene therapeutic solutions for treating multiple diseases. It has developed gene therapies that aim to help patients suffering from rare diseases. Products include FBX-101 which helps to treat infantile Krabbe diseases, FBX-201 for rare and monogenic diseases, and FBX-301 for rare & cancer diseases.
- Sep 2022Series C$90M
- Jan 2022Conventional Debt$80M
- Apr 2021Series B$120M
- Jul 2020Series A$40M
#4
Deadpooled · Cleveland, Ohio · founded 2007 · 1 employees$107.3Mraised▾
Developer of non-viral gene therapies to treat cardiovascular diseases that target natural repair pathways. The company's product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1 (SDF-1), a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Focused on developing JVS-100 for the treatment of advanced chronic heart failure and late-stage peripheral artery disease (PAD).
- Oct 2021Series C$64.2M
- Oct 2017Conventional Debt$1.3M
- May 2015Series B$7.5M
- May 2015Conventional Debt$6M
#5
Funding Raised · Twinsburg, Ohio · founded 2002$9.8Mraised▾
GLC Biotechnology is a developer of DNA tests for early detection of colon cancer. The company has developed technology for stool DNA tests for colon cancer screening to detect colon precancerous tumors. The company has developed proprietary, patented methods for DNA extraction from stool. The DNA and biomarker are extracted fro stool to analyze the biomarker for precancerous tumors.
- Sep 2023Grant (prize money)$2M
- Sep 2019Grant (prize money)$2M
- Sep 2019Grant (prize money)$1.5M
- Jun 2019Grant (prize money)$225K
#6
Acquired · Mason, Ohio · founded 2006 · 390 employees$84.5Mraised▾
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients suffering from neuropsychiatric and other medical conditions. Assurex Health’s proprietary Genesight technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
- Dec 2015Series D$15M
- Dec 2014Series D$37.4M
- Oct 2014Grant (prize money)$6M
- May 2014Conventional Debt$25M
#7
Series A · Columbus, Ohio · founded 2016 · 16 employees$11.6Mraised▾
ParaGen Technologies is involved in developing tissue engineering technologies. They have developed their own synthetic nanofiber scaffolds, which replicates the extracellular matrix and enables healing by mimicking the physical structures present naturally in our body. Their technology can be used for wound care, orthopedics, vascular, and hernia repair.
- Nov 2021Series A$4.4M
- Apr 2019Seed$3.1M
- Nov 2018Conventional Debt$3M
- Dec 2017Seed$4.1M
#8
Series A · Oxford, Ohio · founded 2009 · 6 employees$5.9Mraised▾
Provider of molecular diagnostic solutions to stroke. The company uses its proprietary ISCDx test which is used to analyze the RNA expression of blood biomarkers to identify the cause of stroke. The company's program Biomarkers of Acute Stroke Etiology (BASE) study (NCT02014896) is an observational study that uses RNA gene expression in to identify the aetiology of acute ischemic stroke.
- May 2019Conventional Debt$1M
- Dec 2017Series A$2.1M
- Sep 2016Conventional Debt$1.7M
- Jul 2015Series A$500K
#9
Acquired · Athens, Ohio · founded 1983 · 1103 employees$10Mraised▾
Diagnostic Hybrids develops and manufactures cellular and molecular diagnostic kits for various applications in detecting a range of respiratory diseases, herpes infections, thyroid function, and other markers of diseases. The company offers a D3 FastPoint L-DFA influenza A/influenza B virus identification kit, which allows for the identification of influenza A virus and influenza B virus from a patient’s specimen in under 30 minutes. It also develops and commercializes genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry with a focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines.
- Aug 2004PE$10M
#10
Acquired · Columbus, Ohio · founded 2017 · 4 employees$2.5Mraised▾
Genetic medicine company engineering solutions for rare diseases. This global biotechnology company is dedicated to engineering precision genetic medicine to transform the lives of individuals impacted by rare diseases. They focus on shortening the drug development timeline, expanding gene therapy manufacturing capacity, and improving access to revolutionary treatments. Their work encompasses gene therapy, RNA technologies, and gene editing. They are dedicated to leveraging science to help patients, particularly in areas like Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and Charcot-Marie-Tooth disease. They are committed to continuous evaluation of other diseases and modalities. They are focused on research and development, clinical trials, and patient affairs. They are also involved in strategic partnerships and investigator-initiated studies. They are committed to corporate responsibility through grants and giving.
- Dec 2017Seed$2.5M
#11
Series A · Franklin, Ohio · founded 2002 · 5 employees$2.3Mraised▾
NanoDetection Technology develops chips for rapid detection of multiple biomarkers. Its platform technology uses 25 separate light sensing diodes to enable multiplexed detection of desired biomarkers at the point-of-care. The company's focus is on infectious diseases, and currently offers assays for MRSA screening, MRSA/MSSA dual screening, sepsis, flu, HCV, sexually transmitted diseases and dengue.
- Jul 2011Series A$300K
- Nov 2010Grant (prize money)$175K
- Nov 2010Series A$2M
#12
Funding Raised · Cleveland, Ohio · founded 2017 · 9 employees$1.4Mraised▾
Cell X Technologies is a developer of regenerative medicine to measure and manage human cell sources. It has developed medicines by using integrated strategies of imaging, analytics, and automation to measure human cells. It has developed a Cell X device that helps users to view the imaging of cell populations in culture. It uses quantitative image analysis of cells and colonies using ASTM standards via ColonyzeTM software. The Cell X platform is designed to be used in a GMP quality environmental control system. It can be paired with a plate mover robot & can be scheduled to manage protocol workflow.
- Sep 2019Grant (prize money)$1.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Ohio is moving
A read on the academic research around Bioinformatics in Ohio — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 139 papers.
- The Ohio State University111
- The Ohio State University Wexner Medical Center15
- Ohio University13
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute7
- Northeast Ohio Medical University2
- Cancer1→5
- Gene1→5
- Cancer2→3
- Epigenetics4
- Cancer4
- microRNA2
- Genetics2
- Computational biology2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.